Latest news
Etienne Morel’s talk at the Virology Virtual Conference
Etienne Morel, collaborator of ENYO Pharma, gave a talk describing the results of our collaboration entitled “From virus-host molecular crosstalk to ER-mitochondria membrane interface mobilization in innate immunity” at the Virology Virtual Conference on March the 23th :
Conference description
New publication : Mitochondrial morphodynamics alteration induced by influenza virus infection as a new antiviral strategy
Together with the team of Etienne Morel, ENYO Pharma continues the antiviral exploration of its molecule targeting the NEET proteins, in the context of influenza virus. In this new article, we demonstrate that MITO-C exerts a membrane signature that strictly counteracts the signature applied by influenza virus infection on the mitochondria and on endoplasmic reticulum-mitochondria contact sites. Consequently, MITO-C potentiates Interferon expression and inhibits viral replication. Publication here
ENYO Pharma selected to take part in the French Tech 120 FT120 program
ENYO Pharma has been selected to take part in the French Tech 120 #FT120 program for the second consecutive year. We will thus benefit from specific guidance and visibility. Created by the French government, this program offers support to French scaleups with the potential to become global technology leaders.
https://lafrenchtech.com/en/how-france-helps-startups/ft120/
New publication : A new class of molecule targeting the NEET family of proteins
ENYO is proud to share international collaborative study showing the development of MITO-C (one compound of EYP002 series) a new class of molecule targeting the
NEET family of protein. This work co-led by Etienne Morel (INEM, Paris, France) and Benoît de Chassey (ENYO Pharma, Lyon France) and sponsored by ENYO Pharma nicely shows that MITO-C (one compound of EYP002 series) modulates mitochondria morphogenesis and stabilizes ER-Mitochondria contact sites. This seminal fundamental results opens potential indications that go beyond infectious diseases e.g.
Vonafexor accepted as the generic name for EYP001 by the WHO
We are pleased to announce that the World Health Organization (WHO) has accepted the international non-proprietary name (INN, or generic name) vonafexor for our FXR agonist lead candidate previously referred to as EYP001.
Latest Press Release 